DE69030044T2 - Tetrazolessigsäurederivate mit Aldosereduktase inhibierender Wirkung - Google Patents

Tetrazolessigsäurederivate mit Aldosereduktase inhibierender Wirkung

Info

Publication number
DE69030044T2
DE69030044T2 DE69030044T DE69030044T DE69030044T2 DE 69030044 T2 DE69030044 T2 DE 69030044T2 DE 69030044 T DE69030044 T DE 69030044T DE 69030044 T DE69030044 T DE 69030044T DE 69030044 T2 DE69030044 T2 DE 69030044T2
Authority
DE
Germany
Prior art keywords
tetrazol
acetic acid
furyl
radical
spectrum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69030044T
Other languages
German (de)
English (en)
Other versions
DE69030044D1 (de
DE384879T1 (de
Inventor
Mitsuzi Agata
Masayoshi Goto
Yoshihiro Horio
Sinji Inukai
Yasuhiro Ootake
Shohei Sawaki
Manami Umezawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wakamoto Pharmaceutical Co Ltd
Original Assignee
Wakamoto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakamoto Pharmaceutical Co Ltd filed Critical Wakamoto Pharmaceutical Co Ltd
Publication of DE69030044D1 publication Critical patent/DE69030044D1/de
Application granted granted Critical
Publication of DE69030044T2 publication Critical patent/DE69030044T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69030044T 1989-10-03 1990-10-03 Tetrazolessigsäurederivate mit Aldosereduktase inhibierender Wirkung Expired - Fee Related DE69030044T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP25708689 1989-10-03

Publications (2)

Publication Number Publication Date
DE69030044D1 DE69030044D1 (de) 1997-04-10
DE69030044T2 true DE69030044T2 (de) 1997-10-09

Family

ID=17301550

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69030044T Expired - Fee Related DE69030044T2 (de) 1989-10-03 1990-10-03 Tetrazolessigsäurederivate mit Aldosereduktase inhibierender Wirkung

Country Status (6)

Country Link
US (2) US5068239A (enExample)
EP (1) EP0421365B1 (enExample)
JP (1) JPH03204875A (enExample)
DE (1) DE69030044T2 (enExample)
HU (2) HU215432B (enExample)
RU (2) RU2052458C1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605795A (en) * 1986-07-24 1997-02-25 Tropix, Inc. Assays using chemiluminescent, enzymatically cleavable substituted 1,2-dioxetanes and kits therefor
JPH04297474A (ja) * 1991-03-26 1992-10-21 Wakamoto Pharmaceut Co Ltd テトラゾール酢酸誘導体
GB9110636D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
US5262433A (en) * 1991-08-06 1993-11-16 Wakamoto Pharmaceutical Co., Ltd. Tetrazoleacetic acid derivatives and method of aldose reductase inhibition therewith
CA2297011C (en) * 1997-07-22 2007-01-30 Shionogi & Co., Ltd. Sulfonamide derivatives as therapeutic or prophylactic agent for glomerulopathy
WO2002028353A2 (en) * 2000-10-05 2002-04-11 Smithkline Beecham Corporation Phosphate transport inhibitors
AU2015215863C1 (en) * 2009-02-06 2016-10-20 Imago Pharmaceuticals, Inc. Inhibitors of jun n-terminal kinase
SG10201407409WA (en) 2009-02-06 2015-01-29 Elan Pharm Inc Inhibitors of jun n-terminal kinase
KR20200140261A (ko) * 2018-04-06 2020-12-15 닛뽕소다 가부시키가이샤 (헤테로)아릴술폰아미드 화합물 및 유해 생물 방제제
JP7361055B2 (ja) * 2018-07-05 2023-10-13 バイエル・アクチエンゲゼルシヤフト 抗菌剤としての置換チオフェンカルボキサミド類及び類縁体
JP7498199B2 (ja) * 2019-06-28 2024-06-11 ファイザー・インク 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8725260D0 (en) * 1987-10-28 1987-12-02 Lilly Industries Ltd Organic compounds

Also Published As

Publication number Publication date
HU211166A9 (en) 1995-11-28
USRE35321E (en) 1996-08-27
HU906305D0 (en) 1991-04-29
DE69030044D1 (de) 1997-04-10
EP0421365B1 (en) 1997-03-05
JPH0583551B2 (enExample) 1993-11-26
RU94031212A (ru) 1996-08-10
EP0421365A2 (en) 1991-04-10
RU2052458C1 (ru) 1996-01-20
HU215432B (hu) 1999-04-28
HUT59132A (en) 1992-04-28
EP0421365A3 (en) 1992-01-02
JPH03204875A (ja) 1991-09-06
US5068239A (en) 1991-11-26

Similar Documents

Publication Publication Date Title
DE1445154C3 (de) 1,4-Dihydro-1,8-naphthyridinderi vate und ein Verfahren zu ihrer Herstellung
DE69318077T2 (de) Triazolylthiomethylthiocephalosporin-Hydrochlorid, sein kristallines Hydrat und seine Herstellung
DE2228012C3 (de) Phthalidester der 6- [D(-)- a Aminophenylacetamido] -penicillansäure und Verfahren zu seiner Herstellung
DE69500597T2 (de) N-pyridyl Carboxamidderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutischen Zusammensetzungen
JPS62161728A (ja) 抗菌剤
DE69030044T2 (de) Tetrazolessigsäurederivate mit Aldosereduktase inhibierender Wirkung
DE69018876T2 (de) Pyridazinon-Derivate.
DE69020394T2 (de) Aldose-Reductase-Inhibitor.
DE69418218T2 (de) Chinolonylcarboxamidocephalosporin-derivate und diese enthaltende arzneimittel
DE69014798T2 (de) Thionaphthalen-derivate, verfahren zur herstellung und antiallergisches mittel daraus.
DE69828516T2 (de) (hetero)aryl-sulfonamid derivate, deren herstellung und deren verwenddung als faktor xa inhibitoren
DD287495A5 (de) Verfahren zur herstellung herterozyclischer stickstoffverbindungen
EP0697405B1 (de) Substituierte-Chinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
CH645354A5 (de) Chinolyl-guanidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mischungen.
DD222025A5 (de) Verfahren zur herstellung neuer flavene oder thioflavene
DE3216843A1 (de) Thiomethylpyridin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0211157B1 (de) Isoxazolderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutischen Präparate
DE2914843A1 (de) 7 alpha -methoxycephalosporin-derivate, verfahren zu deren herstellung und deren verwendung
CH629209A5 (en) Process for preparing penicillin derivatives
CH634566A5 (de) Benzylpyrimidine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
DE60015931T2 (de) Verfahren zur herstellung eines chiralen-beta-aminosäureesters
DE69713128T2 (de) 4-(1-piperazinyl)benzosäurederivate, verfahren zu ihrer herstellung und ihre therapeutischen verwendungen
CH634848A5 (de) Verfahren zur herstellung neuer 7-(n-substituierter 2-phenylglycinamido)-3-substituierte-3-cephem-4-carbonsaeuren.
CH634315A5 (de) Verfahren zur herstellung von substituierten 2-vinylchromonen.
DD222311A5 (de) Verfahren zur herstellung neuer flavanone und thioflavanone

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee